• Explore /
  • Poster
  • / Antitumor activity of olverembatinib (HQP1351) in patients (pts) with tyrosine kinase inhibitor (TKI)–resistant succinate dehydrogenase (SDH)–deficient gastrointestinal stromal tumor (GIST).

Antitumor activity of olverembatinib (HQP1351) in patients (pts) with tyrosine kinase inhibitor (TKI)–resistant succinate dehydrogenase (SDH)–deficient gastrointestinal stromal tumor (GIST).

Abstract Poster

Authors

Haibo Qiu

Haibo Qiu

State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Sun Yat-sen University Cancer Center, Sun Yat-sen University, Guangzhou, China

Haibo Qiu , Zhi-wei Zhou , Ye Zhou , Xiangbin Wan , Ning Li , Kaixiong Tao , Yong Li , Xin Wu , Zi Chen , Lihui Liu , Lichuang Men , Hengbang Wang , Eric Liang , Cunlin Wang , Lixin Jiang , Dajun Yang , Rui-Hua Xu , Yifan Zhai

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2023 ASCO Annual Meeting

Session Type

Poster Session

Session Title

Sarcoma

Track

Sarcoma

Sub Track

Gastrointestinal Stromal Tumors (GIST)

Clinical Trial Registration Number

NCT03594422

Citation

J Clin Oncol 41, 2023 (suppl 16; abstr 11540)

DOI

10.1200/JCO.2023.41.16_suppl.11540

Abstract #

11540

Poster Bd #

474

Abstract Disclosures

Similar Posters

First Author: Haibo Qiu

First Author: Charles B. Nguyen

First Author: Yanzhe Xia

First Author: Antoine Desilets